Skip to content
Biodatica
Start free

Chimeric Therapeutics

Atlanta, Georgia

OncologyCAR-TPhase II
Compare Sign in to watch

What changed

NIH UG1 · $0.4M · Abramson Cancer Center Lead Academic Participating Sites (LAPS)

2mo agoNew grantApr 21, 2026Source filing (opens the source filing in a new tab)

Momentum

67no change

Momentum 67 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

665 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    UG1 · $369k · non-dilutive

    Apr 20, 2026

    UNIVERSITY OF PENNSYLVANIA · PI EADS, JENNIFER RACHEL · NCI · award ends Feb 29, 2032 · Abramson Cancer Center Lead Academic Participating Sites (LAPS)

    NIH RePORTER · NIH RePORTER 11291365 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    May 15, 2024

    Neuroendocrine Tumors, Colorectal Cancer, Gastric Cancer · RECRUITING · sponsor: Chimeric Therapeutics · A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

    ClinicalTrials.gov · NCT06055439 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources